No material surprise vs expectations, the stock will trade on Phase 3 enrollment updates and BIM-DRS FIH trial initiation in H2 2026. Monitor for any enrollment delays or safety signals in the ongoing registrational trials.
SGP drugs
SGP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $23.21entry
- T+1 · 6mo ago −4.18%α −4.12% · $22.24
- T+5 · 6mo ago −10.21%α −11.17% · $20.84
- T+20 · 5mo ago −20.55%α −22.67% · $18.44
- T+60 · 3mo ago +7.07%α +2.55% · $24.85
Price Chart
How similar events traded
Executive Summary
SpyGlass Pharma reported Q1 2026 net loss of $13.8M ($-0.69/share), in line with the $-0.67 consensus estimate. The company highlighted $251M cash runway through 2028 and on-track Phase 3 enrollment for its BIM-IOL System, with BIM-DRS FIH trial expected in H2 2026. This is a pre-revenue clinical-stage biotech filing with no revenue to report, the focus is on pipeline execution and cash position.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $13.8M, or ($0.69) per basic/diluted share, vs consensus estimate of ($0.67)
- Cash, cash equivalents and short-term investments of $251.0M as of March 31, 2026, expected to fund operations through 2028
- Phase 3 trials (SGP-005 and SGP-006) enrollment on track with completion expected in 2027
- BIM-DRS first-in-human trial on track to start in H2 2026
- No revenue reported, pre-revenue clinical-stage company
- R&D expenses $8.5M (up from $6.1M YoY); G&A expenses $6.9M (up from $1.4M YoY) due to clinical hiring and public company costs
- IPO in February 2026 raised $172.5M in gross proceeds
Financial Impact
Net loss of $13.8M in Q1 2026, in line with consensus of ($0.67) per share; cash position $251M provides runway through 2028
Risk Factors
- Clinical trial enrollment delays or failure in Phase 3 BIM-IOL trials
- Cash burn rate may accelerate if trials expand or take longer than expected
- Regulatory risk, FDA approval not guaranteed for BIM-IOL System
- Competition from existing glaucoma treatments and other drug delivery platforms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001778922-26-000033 |
| Document: sgp-20260514.htm | 0001778922-26-000033 |
| Document: 0001778922-26-000033-index-headers.html | 0001778922-26-000033 |
| Document: 0001778922-26-000033-index.html | 0001778922-26-000033 |
| Document: 0001778922-26-000033.txt | 0001778922-26-000033 |
| 8-K Data (Synthetic) | 0001778922-26-000033 |
Track record
9 reports on SGP
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 No price data
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
- Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
- May 14, 202626w ago 8-K Neutral 4/10 Viewing Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
- Mar 26, 202633w ago Press Release Bullish 8/10 Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
- Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers